DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.

Background Platinum compounds are the mainstay of chemotherapy for lung cancer. Unfortunately treatment failure remains a critical issue since about 60 % of all non-small cell lung cancer (NSCLC) patients display intrinsic platinum resistance.